NeuroThera's C$5.4M Financing Locks in C$30M Valuation for SciSparc Stake
SPRC has more than doubled off its 52-week low of $2.98 on light trading volume (0.3× avg).
Summary
NeuroThera Labs completed a C$5.4 million private placement, with SciSparc investing C$2.7 million and holding a stake valued at approximately C$30 million.
Key Events · Financing and Capital Events · SPRC
-
NeuroThera Completes C$5.4M Financing
NeuroThera Labs completed two tranches of non-brokered private placements raising aggregate gross proceeds of C$5.4 million.
-
SciSparc Invests C$2.7M
SciSparc subscribed for 22,500,000 units at C$0.12 per unit, representing 50% of the total gross proceeds raised.
-
Stake Valued at C$30M
Following the financing, SciSparc holds approximately 44.6% of NeuroThera's issued and outstanding common shares, valued at approximately C$30 million.
-
Warrant Terms and Acceleration
Each unit includes one warrant exercisable at C$0.16 per share for 36 months, with an acceleration provision upon Nasdaq listing of NeuroThera's securities.
Analysis · SPRC · Life Sciences
A completed private placement at NeuroThera Labs, SciSparc's majority-owned subsidiary, has crystallized the value of its position. The C$5.4 million raise included a C$2.7 million investment from SciSparc for 22.5 million units at C$0.12 per unit. Following the financing, SciSparc holds approximately 44.6% of NeuroThera, a stake now valued at roughly C$30 million. The capital strengthens NeuroThera's balance sheet for working capital and corporate expenses, while the warrant structure includes an acceleration provision tied to a potential Nasdaq listing. For SciSparc shareholders, this is a significant capital event at the subsidiary level.
At the time of this filing, SPRC was trading at $6.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $2.98 to $80.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.